KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Equity Average: 2011-2025

Historic Equity Average for Neogenomics (NEO) over the last 12 years, with Sep 2025 value amounting to $846.2 million.

  • Neogenomics' Equity Average fell 7.22% to $846.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $846.2 million, marking a year-over-year decrease of 7.22%. This contributed to the annual value of $921.9 million for FY2024, which is 4.93% down from last year.
  • Per Neogenomics' latest filing, its Equity Average stood at $846.2 million for Q3 2025, which was down 2.87% from $871.2 million recorded in Q2 2025.
  • Neogenomics' 5-year Equity Average high stood at $1.1 billion for Q3 2021, and its period low was $769.0 million during Q1 2021.
  • Over the past 3 years, Neogenomics' median Equity Average value was $919.6 million (recorded in 2024), while the average stood at $920.9 million.
  • Per our database at Business Quant, Neogenomics' Equity Average surged by 73.07% in 2021 and then fell by 10.44% in 2022.
  • Quarterly analysis of 5 years shows Neogenomics' Equity Average stood at $1.1 billion in 2021, then fell by 10.44% to $1.0 billion in 2022, then decreased by 6.07% to $944.5 million in 2023, then fell by 4.15% to $905.3 million in 2024, then declined by 7.22% to $846.2 million in 2025.
  • Its last three reported values are $846.2 million in Q3 2025, $871.2 million for Q2 2025, and $895.3 million during Q1 2025.